|
1.Qiu Z, Pang X, Xiang Q, Cui Y*. The Crosstalk between Nephropathy and Coagulation Disorder: Pathogenesis, Treatment, and Dilemmas.
J Am Soc Nephrol. 2023, 34(11):1793-1811.
2.Pang X#, Sun X#, Gu Y#, He X, Gong, Song S, Zhang J, Xia J, Liu Z*, Cui Y*. Discovery of C19-9 as a novel non-RGD inhibitor of
αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer. Signal transduct tar,2023, 8(1), 60.
3.Pang X#, He X#, Qiu Z#, Zhang H#, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q*, Cui Y*. Targeting integrin pathways:
mechanisms and advances in therapy. Signal transduct tar,2023, 8(1): 1.
4.Wang G#, Zhao K#, Han J#, Hu Z#, Zhang T, Wang Y, Shi R, Li Y, Song Q, Du H, He P, Xu S, Yang X, Fu Y, Cui Y*, Xie L*.
Safety and Immunogenicity of a Bivalent SARS-CoV-2 Recombinant Protein Vaccine, SCTV01C in Unvaccinated Adults:
A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial. J Infect. 2023, 86(2):154-225.
5.Xiang Q, Wang Z, Mu G, Xie Q, Liu Z, Zhou S, Zhang H, Wang Z, Jiang J, Hu K, Zhang Y, Zhao Z, Yuan D, Guo L, Wu T, Zhang J,
Wang N, Xiang J, Gu Z, Sun J, Cui Y*. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban
in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study. Clin Transl Med. 2023, 13(5):e1263.
6.Su X, Wang H, Zhao N, Wang T*, Cui Y*. Trends in innovative drug development in China. Nat Rev Drug Discov.
2022, 21(10), 709–710.
7.Xiang Q, Xie Q, Liu Z, Mu G, Zhang H, Zhou S, Wang Z, Wang Z, Zhang Y, Zhao Z, Yuan D, Guo L, Wang N, Xiang J, Song H,
Sun J, Jiang J, Cui Y*. Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese
patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study. Clin Transl Med.
2022, 12(12):e1104.
8.Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G, Qian L, Deng H, Li H, Huo Y.* A Potential Long-Acting LDL-Cholesterol-Lowering
PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies. JACC Asia, 2021, 1(3), 411–415.
9.Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, Cui Y*. Accuracy of HAS-BLED and other bleeding risk assessment tools in
predicting major bleeding events in atrial fibrillation: A network meta-analysis. J Thromb Haemost. 2020, 18(4):791-801.
10.Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y*. Progress in the development of antiplatelet agents: Focus on the
targeted molecular pathway from bench to clinic. Pharmacol Ther. 2019, 203:107393.
11.Pang X, Gong K, Zhang X, Wu S, Cui Y*, Qian B*. Osteopontin as a multifaceted driver of bone metastasis and drug resistance[J].
Pharmacol Res, 2019, 144:235-44.
12.崔一民,刘泽源,阳国平等.科学设定健康志愿者参与临床试验间隔期的建议[J].中国临床药理学杂志,2022,38(17):2106-2112.
|
